EMA Authorised: Xultophy (insulin degludec;liraglutide) — Novo Nordisk A/S

View source ↗

Summary

The European Medicines Agency authorised Xultophy, a fixed-dose combination of insulin degludec and liraglutide, for adults with type 2 diabetes mellitus in the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Xultophy (insulin degludec and liraglutide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Novo Nordisk A/S. Decision date: 25/10/2024